Viracta Therapeutics Inc (VIRX)
$0.830946
Live
Insights on Viracta Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 86.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 331.1%
Performance
- $0.82$0.86$0.83
1.19%
Downside
Day's Volatility :5.08%
Upside
3.94%
- $0.43$2.38$0.83
48.19%
Downside
52 Weeks Volatility :81.93%
Upside
65.13%
Returns
| Period | Viracta Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 65.97% | 1.7% | 0.0% |
6 Months | 27.74% | 11.3% | 0.0% |
1 Year | -36.64% | 5.4% | 1.3% |
3 Years | -91.55% | 13.9% | -22.1% |
Highlights
Market Capitalization | 33.3M |
Book Value | $0.33 |
Earnings Per Share (EPS) | -1.32 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -41.5% |
Return On Equity TTM | -128.57% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -50.2M |
Diluted Eps TTM | -1.32 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.16 |
EPS Estimate Next Year | -1.12 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.29 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 742.41%
Technicals Summary
Sell
Neutral
Buy
Viracta Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Viracta Therapeutics Inc | -21.1% | 27.74% | -36.64% | -91.55% | -94.67% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Viracta Therapeutics Inc | 1.23 | NA | NA | -1.16 | -1.29 | -0.41 | NA | 0.33 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Viracta Therapeutics Inc | Buy | $33.3M | -94.67% | 1.23 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Bvf Inc
9.20%Citadel Advisors Llc
3.87%Vanguard Group Inc
2.96%LAURION CAPITAL MANAGEMENT LP
1.78%Samsara BioCapital, LLC
1.76%Mccormack Advisors International
0.91%
Company Information
viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus, and will pursue opportunities to address other serious virus-associated disease.
Organization | Viracta Therapeutics Inc |
Employees | 40 |
CEO | Mr. Mark Andrew Rothera |
Industry | Healthcare |
Discover More
Acorda Therapeutics, Inc.
$0.83
-0.64%
Sight Sciences Inc
$0.83
-0.64%
Sangamo Therapeutics, Inc.
$0.83
-0.64%
Corbus Pharmaceuticals Holdings, Inc.
$0.83
-0.64%
Redhill Biopharma Ltd-sp Adr
$0.83
-0.64%
Fusion Pharmaceuticals Inc
$0.83
-0.64%
Geron Corporation
$0.83
-0.64%
Iradimed Corp
$0.83
-0.64%
Dbv Technologies S.a.
$0.83
-0.64%